BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...